Heartbeam (BEAT) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
Heart attack assessment became the primary strategic focus, with FDA Breakthrough Device Designation, TAP acceptance and agreement on a 510(k) pathway advancing the program.
ALIGN-ACS showed comparable HeartBeam 3D ECG accuracy to standard 12-lead ECG; a U.S. pivotal study is planned to begin in Q1 2027.
Q3 losses, expenses and cash use declined; approximately $4.0M of Q4 ATM proceeds lifted unaudited pro forma cash to $10.1M.
The FDA-cleared system is limited to arrhythmia assessment; heart attack detection and AI applications remain investigational.
Financial highlights
Q3 operating expenses were $3.457M, down from $5.092M in Q2 2026 and $5.290M in Q3 2025; net loss was $3.010M versus $5.039M and $5.255M, respectively.
Q3 net loss per share was $0.05 versus $0.10 in Q2 2026 and $0.15 in Q3 2025; nine-month net loss was $12.749M versus $15.713M.
Nine-month operating expenses were $13.265M versus $15.829M; R&D was $6.816M versus $10.096M, while SG&A was $6.449M versus $5.733M.
No revenue was generated through September 30, 2026; no material commercial revenue is expected in 2026.
Outlook and guidance
FY2026 net operating cash outflow guidance is $12.0M–$12.5M, reduced from prior guidance of less than $14M; baseline Q4 operating cash outflow is expected below $2.5M.
Pivotal-study design is targeted for completion in Q4 2026, with enrollment planned for Q1 2027 and completion targeted by mid-2027; accelerated timing could increase Q4 spending.
Management described a likely pivotal study of about 300 patients across 8–10 centers; FDA agreement on study size and endpoints remains pending.
Latest events from Heartbeam
- Commercial launch is underway as clinical studies advance a broader cardiac platform opportunity.BEAT
Investor presentation - Clinical and commercial progress accelerated, cash runway extended, but liquidity risks remain.BEAT
Q2 2026 - Directors and auditor approved; equity plan amendment failed; updates set for August.BEAT
AGM 2026 - Two board nominees, including the CEO, have withdrawn from re-election with no replacements named.BEAT
Proxy filing - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 2026 - AIMIGo nears FDA clearance as Q2 loss hits $5M, cash burn raises going concern risk.BEAT
Q2 2024